In Cre+ recipients, tamoxifen exposure should ablate IFNαβR expression, and these mice should recapitulate the published findings with conventional germline IFNαβR knockout mice [6,7,16,17,20,21], which are unable to control primary viral infection, and in which the expansion of virus-specific T cells is severely compromised. The gene discussed is IFNAR2; the disease is viral infectious disease.